Bank of America
OVID icon

Bank of America’s Ovid Therapeutics OVID Stock Holding History

Bank of America’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$645K Buy
290,432
+95,532
+49% +$171K ﹤0.01% 4760
2025
Q4 		$318K Sell
194,900
-167,807
-46% -$258K ﹤0.01% 5128
2025
Q3 		$472K Buy
362,707
+347,799
+2,333% +$301K ﹤0.01% 5824
2025
Q2 		$4.9K Sell
14,908
-16,842
-53% -$5.07K ﹤0.01% 7297
2025
Q1 		$9.87K Sell
31,750
-24,983
-44% -$15.4K ﹤0.01% 7116
2024
Q4 		$52.9K Buy
56,733
+18,841
+50% +$21.1K ﹤0.01% 6618
2024
Q3 		$44.7K Buy
37,892
+8,358
+28% +$8.73K ﹤0.01% 6577
2024
Q2 		$22.7K Buy
29,534
+10,946
+59% +$30.5K ﹤0.01% 6708
2024
Q1 		$56.7K Sell
18,588
-35,720
-66% -$120K ﹤0.01% 6470
2023
Q4 		$175K Buy
54,308
+14,612
+37% +$49.9K ﹤0.01% 6140
2023
Q3 		$152K Sell
39,696
-12,715
-24% -$45.7K ﹤0.01% 6045
2023
Q2 		$172K Buy
52,411
+39,299
+300% +$133K ﹤0.01% 5939
2023
Q1 		$33.8K Buy
13,112
+9,675
+281% +$22.9K ﹤0.01% 6614
2022
Q4 		$6.39K Sell
3,437
-8,314
-71% -$14.2K ﹤0.01% 7021
2022
Q3 		$22K Sell
11,751
-4,556
-28% -$9.53K ﹤0.01% 6994
2022
Q2 		$35K Sell
16,307
-25,291
-61% -$61.1K ﹤0.01% 6984
2022
Q1 		$131K Buy
41,598
+39,875
+2,314% +$125K ﹤0.01% 6721
2021
Q4 		$6K Sell
1,723
-31,949
-95% -$109K ﹤0.01% 7794
2021
Q3 		$114K Sell
33,672
-35,430
-51% -$129K ﹤0.01% 6648
2021
Q2 		$270K Buy
69,102
+46,678
+208% +$184K ﹤0.01% 5865
2021
Q1 		$90K Buy
22,424
+7,025
+46% +$23.3K ﹤0.01% 6438
2020
Q4 		$36K Sell
15,399
-7,012
-31% -$32.7K ﹤0.01% 6441
2020
Q3 		$128K Buy
22,411
+1,524
+7% +$10.2K ﹤0.01% 5553
2020
Q2 		$154K Sell
20,887
-27,303
-57% -$128K ﹤0.01% 5421
2020
Q1 		$144K Buy
+48,190
New +$162K ﹤0.01% 5299
2019
Q4 		– Sell
-3,007
Closed -$10K – 7306
2019
Q3 		$10K Sell
3,007
-6,190
-67% -$14.1K ﹤0.01% 6723
2019
Q2 		$17K Sell
9,197
-19,637
-68% -$35.1K ﹤0.01% 6610
2019
Q1 		$51K Buy
28,834
+3,989
+16% +$9.98K ﹤0.01% 6187
2018
Q4 		$60K Buy
24,845
+20,525
+475% +$93.7K ﹤0.01% 6150
2018
Q3 		$24K Buy
4,320
+1,331
+45% +$10.1K ﹤0.01% 6455
2018
Q2 		$23K Buy
2,989
+2,070
+225% +$17.8K ﹤0.01% 6472
2018
Q1 		$6K Buy
919
+299
+48% +$2.42K ﹤0.01% 6733
2017
Q4 		$6K Buy
620
+383
+162% +$3.52K ﹤0.01% 6706
2017
Q3 		$2K Buy
+237
New +$1.97K ﹤0.01% 6866

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bank of America's OVID Position: Q1 2026 in Review

Bank of America increased its Ovid Therapeutics (OVID) stake by 49% in Q1 2026, buying an estimated $171K and bringing the position to 290,432 shares worth $645K. The position accounts for ﹤0.01% of the portfolio, ranked #4760.

Bank of America first reported a position in OVID in Q3 2017 and has held it in 34 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Bank of America held 290,432 shares of Ovid Therapeutics worth $645K as of Q1 2026.
  • Bank of America bought 95,532 Ovid Therapeutics shares in Q1 2026, an estimated $171K.
  • Ovid Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4760 holding.
  • Bank of America first reported a position in Ovid Therapeutics in Q3 2017 and has held it in 34 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.